Stifel Financial Corp trimmed its stake in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 0.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,837,046 shares of the company’s stock after selling 1,492 shares during the quarter. Stifel Financial Corp owned approximately 5.43% of Biohaven Pharmaceutical worth $118,362,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its stake in Biohaven Pharmaceutical by 511.1% in the third quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $46,000 after purchasing an additional 920 shares during the last quarter. Tower Research Capital LLC TRC acquired a new position in Biohaven Pharmaceutical in the second quarter valued at $65,000. Aperio Group LLC acquired a new position in Biohaven Pharmaceutical in the second quarter valued at $71,000. Glen Harbor Capital Management LLC increased its stake in Biohaven Pharmaceutical by 165.9% in the second quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock valued at $76,000 after purchasing an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC acquired a new position in Biohaven Pharmaceutical in the third quarter valued at $83,000. 93.52% of the stock is owned by institutional investors.
Several equities research analysts have commented on BHVN shares. Morgan Stanley set a $50.00 price target on Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Oppenheimer set a $67.00 price target on Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, October 9th. ValuEngine lowered Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Wedbush started coverage on Biohaven Pharmaceutical in a research note on Wednesday, November 27th. They set an “outperform” rating and a $75.00 price target for the company. Finally, Zacks Investment Research lowered Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $72.09.
Shares of NYSE BHVN traded up $0.26 on Wednesday, hitting $54.02. The company had a trading volume of 622,176 shares, compared to its average volume of 708,878. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $29.17 and a 12-month high of $67.86. The business has a 50 day moving average of $49.63 and a two-hundred day moving average of $47.14. The firm has a market capitalization of $2.99 billion, a P/E ratio of -8.78 and a beta of 0.46.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.47). Equities research analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -7.55 EPS for the current year.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.